# Immunologic Impact of Dupilumab in Patients Suffering From Asthma and Chronic Rhinosinusitis With Polyps

> **NCT06556264** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Dr. Andrew Thamboo, MD** · enrollment: 60 (estimated)

## Conditions studied

- Chronic Rhinosinusitis With Nasal Polyps
- Asthma

## Interventions

- **DRUG:** Dupilumab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06556264
- **Lead sponsor:** Dr. Andrew Thamboo, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-08
- **Primary completion:** 2025-01
- **Final completion:** 2025-12
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2024-08-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06556264

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06556264, "Immunologic Impact of Dupilumab in Patients Suffering From Asthma and Chronic Rhinosinusitis With Polyps". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06556264. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*